Table 4.

Subanalyses of Psychopathology: Continuous Outcomes

Subanalyses by Medication Class
Total Psychopathology	N Studies	N Participants	Hedges’ g	95% CI	P	I2%
SGAs	6	196	−0.42	−0.92,0.08	0.10	65
Alpha 2 Antagonists	5	139	−0.37	−0.94,0.20	0.20	62
Mirtazapine	4	115	−0.50	−1.17,0.16	0.14	66
Serotonergic Ads	4	285	−0.40	−1.02,0.23	0.21	79
SSRIs	3	245	−0.08	−0.47,0.31	0.67	38
Noradrenergic ADs	3	107	−0.26	−1.23,0.71	0.59	83

Positive Symptoms	N	n	Hedges’ g	95% CI	P	I2%
SGAs	6	196	−0.01	−0.44,0.43	0.98	56
Alpha 2 Antagonists	5	139	−0.50	−1.12,0.12	0.12	68
Mirtazapine	4	115	−0.53	−1.33,0.27	0.19	76
Serotonergic ADs	4	285	0.07	−0.30,0.43	0.72	44
SSRIs	3	245	0.09	−0.44,0.61	0.75	62
Noradrenergic ADs	3	107	0.09	−0.30,0.48	0.65	0

Negative Symptoms	N	n	Hedges’ g	95% CI	P	I2%
SGAs	6	196	−0.28	−0.84,0.27	0.32	72
Alpha 2 Antagonists	5	139	−0.42	−0.96,0.12	0.13	58
Mirtazapine	4	115	−0.55	−1.17,0.07	0.08	61
Serotonergic ADs	4	285	−0.32	−0.96,0.32	0.32	80
SSRIs	3	245	−0.03	−0.55,0.48	0.90	61
Noradrenergic ADs	3	107	−0.39	−1.37,0.58	0.43	83

Depression (HAM-D-predominant)	N	n	Hedges’ g	95% CI	P	I2%
SGAs	5	178	0.00	−0.60,0.60	1.00	74
Alpha 2 Antagonists	4	118	0.05	−0.46,0.55	0.85	46
Mirtazapine	3	94	0.01	−0.68,0.71	0.97	63
Serotonergic ADs	4	304	−0.39	−0.61,−0.16	0.0009	0
SSRIs	3	264	−0.33	−0.57,−0.08	0.009	0

Depression (CDSS-predominant)	N	n	Hedges’ g	95% CI	P	I2%
SGAs	5	178	−0.08	−0.62,0.47	0.78	68
Alpha 2 Antagonists	4	118	−0.06	−0.44,0.32	0.76	9
Mirtazapine	3	94	−0.12	−0.62,0.38	0.64	31
Serotonergic ADs	4	304	−0.51	−0.74,−0.28	<0.0001	0
SSRIs	3	264	−0.47	−0.71,−0.22	0.0002	0

Negative Hedges’ g favors treatment group; random effects models

Bolded p-values: p < 0.05

Abbreviations: AD=Antidepressants; CDSS: Calgary Depression Scale for Schizophrenia; HAM-D: Hamilton Depression Rating Scale